Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;75(4):1109-17.
doi: 10.1111/j.1365-2125.2012.04441.x.

What can we learn from parents about enhancing participation in pharmacovigilance?

Janine Arnott  1 , Hannah Hesselgreaves, Anthony J Nunn, Matthew Peak, Munir Pirmohamed, Rosalind L Smyth, Mark A Turner, Bridget Young
Affiliations

What can we learn from parents about enhancing participation in pharmacovigilance?

Janine Arnott et al. Br J Clin Pharmacol. 2013 Apr.

Abstract

Aims: To investigate parents' views and experiences of direct reporting of a suspected ADR in their child.

Methods: We audio-recorded semi-structured qualitative interviews with parents of children with suspected ADRs. Our sample included parents with (n = 17) and without (n = 27) previous experience of submitting a Yellow Card.

Results: Parents in both groups described poor awareness of the Yellow Card Scheme. Parents who had participated in the Yellow Card Scheme were generally happy to report their child's ADR via the Scheme and valued the opportunity to report concerns independently of health practitioners. They expressed motivations for reporting that have not previously been described linked to the parental role, including how registering a concern about a medicine helped to resolve uncomfortable feelings about their child's ADR. Parents who had not previously submitted a Yellow Card expressed uncertainty about the legitimacy of their involvement in reporting and doubts about the value of the information that they could provide.

Conclusion: Promoting wider participation in pharmacovigilance schemes will depend on raising public awareness. Additionally, our findings point to the need to empower lay people to submitting reports and to reassure them about the value of their reports.

PubMed Disclaimer

References

    1. Medicines and Healthcare products Regulatory Agency (MHRA) Healthcare professional reporting: adverse drug reactions. Available at http://yellowcard.mhra.gov.uk/ (last accessed 1 August 2012)
    1. Medicines and Healthcare products Regulatory Agency (MHRA) Safety information. Available at http://yellowcard.mhra.gov.uk/ (last accessed 1 August 2012)
    1. t'Jong GW, Stricker BHC, Choonara I, van den Anker JN. Lack of effect of the European guidance on clinical investigation of medicines in children. Acta Paediatr. 2002;91:1233–1238. - PubMed
    1. Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJM, Aronson JK, Grahame-Smith DG. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol. 1996;42:423–429. - PMC - PubMed
    1. Vallano A, Cereza G, Pedròs C, Agusti A, Danés I, Aguilera C, Arnau JM. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005;60:653–658. - PMC - PubMed

Publication types